RecruitingNCT05196087

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Sponsor

University Health Network, Toronto

Enrollment

500 participants

Start Date

Jul 20, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Melanoma Gastrointestinal Neuroendocrine Tumor

Summary

Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Patients with histological confirmation of a solid tumor.
Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
Patient must be ≥ 18 years old.
All patients must have signed and dated an informed consent form.